AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00727324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bovine intestinal alkaline phosphatase (BIAP)
Description: 30,000U/24h for 7 consecutive days via a duodenal catheter
Study NCT01460160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Tablets, Oral, 60 mg/m2, Once daily, 2 years or until unacceptable toxicity
Study NCT02544828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Sucrose 200mg
Description: Iron Sucrose 200mg is administered after anesthesia induction.
Study NCT02544828 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo (normal saline) is administered after anesthesia induction
Study NCT05806502 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Nω-hydroxy-nor-arginine
Description: Arginase inhibitor
Study NCT03833128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose REN001
Description: Oral
Study NCT03833128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose REN001
Description: Oral
Study NCT01379027 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pure self-help Internet CBT for depression
Description: Internet, CBT, Depression
Study NCT01379027 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided self-help Internet CBT
Description: CBT, Depression, Website intervention, coaching
Study NCT01379027 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepped-Care Internet CBT condition
Description: Depression CBT, Internet intervention
Study NCT02424591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Infusion at a rate of 10 mcg/kg/min
Study NCT02424591 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV
Study NCT02446795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib: 50mg once daily orally for 4 weeks followed by 2 weeks off treatment (either at 8 a.m. or at 8 p.m.)
Study NCT02446795 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sunitinib
Description: Sunitinib: 50mg once daily orally for 4 weeks followed by 2 weeks off treatment (either at 8 a.m. or at 8 p.m.)
Study NCT02446795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoquercetin
Description: Isoquercetin: 225mg twice a day(at 08 a.m. and at 4 p.m)/Isoquercetin: 450 mg twice a day(at 08 a.m. and at 4 p.m).
Study NCT02446795 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: 225mg twice a day(at 08 a.m. and at 4 p.m)/Placebo: 450 mg twice a day(at 08 a.m. and at 4 p.m).
Study NCT02038686 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PFN-A
Study NCT01488565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine and eltrombopag
Description: Standard: azacitidine D1-5, 8\&9, until loss of clinical benefit. Experimental: eltrombopag at a dose ranging from 50-300mg for 6 months, continuing only in those deriving clinical benefit.
Study NCT02481492 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No flip technique of Shang Ring circumcision
Description: Measure the diameter of the penis with a scale plate of holes, the diameter of the ring was accordance with the glands, inner ring is placed into foreskin cavity, apply the outer ring on the skin covering inner ring, clamp the out ring and cut the redundant foreskin; Ring is detached spontaneously.
Study NCT02481492 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flip technique of Shang Ring circumcision
Description: Measure the diameter of the penis with a scale plate of holes, the diameter of the ring was accordance with the penis, inner ring is placed around the penis, flip foreskin over the inner ring, apply the outer ring on the skin covering inner ring, clamp the out ring and cut the redundant foreskin; Remove the ring 7days postoperatively.
Study NCT01555801 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: submucosal injection needle ; EUS
Description: The patients will accepted submucosal injection of 5ml saline followed by ordinary endosonography(EUS) before surgery or endoscopic dissection.
Study NCT01555801 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ordinary endosonography(EUS)
Description: These patients will be accepted ordinary EUS followed by surgery or endoscopic dissection.
Study NCT01552122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odanacatib
Description: Odanacatib 50 mg compressed tablet will be administered orally, once-a-week, for 24 months
Study NCT01552122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate
Description: Alendronate 70 mg compressed tablets will be administered orally, once-a-week, for 24 months; and a reduced dose of 35 mg will be administered in the same fashion to a subset of women, Japanese participants only, for the same 24-month duration.
Study NCT01552122 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (odanacatib)
Description: One compressed tablet administered orally, once-a-week, for 24 months.
Study NCT01552122 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol (Vitamin D3)
Description: Two (2) 2800 IU compressed tablets administered orally, once-a-week, for 24 months.
Study NCT03389451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga-68 PSMA-HBED-CC PET
Description: Ga-68 PSMA-HBED-CC is an investigational PET drug (radionuclide), that binds to the prostate specific receptors. The dose will be about 5mCi (range 3-7 mCi) and administered intravenously.
Study NCT01552122 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (Vitamin D3)
Description: Two (2) 2800 IU compressed tablets administered orally, once-a-week, for 24 months.
Study NCT01552122 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium carbonate
Description: Dietary and supplemental sources, taken as needed, to ensure a total daily calcium intake of approximately 1200 mg.
Study NCT01552122 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium carbonate
Description: Dietary and supplemental sources, taken as needed, to ensure a total daily calcium intake of approximately 1200 mg.
Study NCT01552122 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (alendronate)
Description: One compressed tablet administered orally, once-a-week, for 24 months.
Study NCT01461330 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DASH diet plus exercise
Description: DASH diet adapted to the usual diet of Brazilian type 2 diabetic patients = prescription of a normocaloric diet including fruits, vegetables, grain products, low fat dairy foods, legumes, without sugar, and with limited fat~Exercises: the recommended physical activity will consist of using a pedometer during the experimental period.
Study NCT01461330 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ADA diet
Description: Adoption of ADA diet.
Study NCT02659917 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glass ionomer
Description: Application of preventive agent
Study NCT02659917 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glass ionomer cement
Description: Application of preventive agent
Study NCT02659917 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: -Glass ionomer-
Description: Atraumatic Restorative Treatment
Study NCT04435977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib 60 MG
Description: • The assigned dose for study treatment is 60 mg qd. Two dose reductions will be permitted (Table 2):~* 60 mg qd to 40 mg qd (level 1)~* 40 mg qd to 20 mg qd (level 2)
Study NCT02394340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg
Description: Oral capsule to be taken as per the instructions regarding proper dosing technique.
Study NCT02394340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luliconazole Cream 1%
Description: Topical cream to be applied as per the instructions regarding proper study drug application technique.
Study NCT02856724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGE2
Description: 10 mg PGE2 vaginal ovul(Propess)
Study NCT02856724 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PGE2
Description: 10 mg PGE2 vaginal ovul(Propess)
Study NCT04008771 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SeeQ CdSe 655 ALT
Description: SeeQ CdSe 655 Alt is a sterile colloidal solution of coated CdSe nanoparticles in a borate buffer suitable for intraocular injection.
Study NCT01585753 — intervention group
Intervention type: DRUG
Intervention: NRTI + PI
Description: tenofovir zidovudine abacavir lamivudine emtricitabine ritonavir darunavir atazanavir lopinavir fosamprenavir
Study NCT01585753 — intervention group
Intervention type: DRUG
Intervention: maraviroc + PI
Description: maraviroc ritonavir darunavir atazanavir lopinavir fosamprenavir
Study NCT01585753 — intervention group
Intervention type: DRUG
Intervention: maraviroc + NRTI
Description: maraviroc tenofovir zidovudine abacavir lamivudine emtricitabine
Study NCT01497964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabazitaxel XRP6258
Description: Pharmaceutical form: solution for infusion Route of administration: intravenous
Study NCT01265979 — intervention group
Intervention type: PROCEDURE
Intervention: Whole body diffusion MRI
Description: These studies will be performed on a 3 Tesla (T) MR system. A major advantage of 3T compared to 1.5T is the improved signal to noise ratio that allows whole-body studies to be faster and without application of external antennas, which greatly improves patient comfort.
Study NCT03637140 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simulated Altitude (FiO2: 15.1%)
Description: Inhalation of deoxygenated air through a altitude simulator (Altitrainer), for approx. 1 hour. given by a facemask.
Study NCT03637140 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shamed Hypoxia (FiO2: 20.9)
Description: Inhalation of unmodified air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask
Study NCT02837939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human derived Transfer factor
Description: One dose (the content of one amp.) of lyophilised drug contains:~Leucocyte dialysatum 200 x 10 to the power of 6 (Lyophilized dialysate from 200 million leukocytes) pH = 7.8 to 9 after reconstitution (dissolving) of drug~To be administered subcutaneously as follows:~12 doses TF in total:~* 3 x TF in first week: day 1,3,5~* 2 x TF in week 2: day 8 , 11~* 1 xTF in week 3 and 4 : day 15, 22~* 1 x TF once a month up to 6 month
Study NCT02837939 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aqua pro injectione 4ml ampules for subcutaneous injection
Description: 12 doses in total:~* 3 doses in first week: day 1,3,5~* 2 doses in week 2: day 8 , 11~* 1 dose in week 3 and 4 : day 15, 22~* 1 dose once a month up to 6 month
Study NCT03088046 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Micronized Progesterone
Description: Anovulatory women with Polycystic ovary syndrome and clinical hyperandrogenism attended in our Hospital will participate in the study. A patient information sheet will be provided and written consent will be obtained. Patients who give written consent will participate in the trial. All patient information will be confidential and only be available to researches involved in the study.~Blood samples will be collected at baseline (Sample #1) and between the 3rd and the 5th day of withdrawal after 7 days of 100mg vaginal MP every 12 hours of administration(Sample#2).
Study NCT02419014 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active CES Device Alpha-Stim®
Description: The Alpha-Stim® device is a Class II FDA-approved device for the delivery of cranial electrotherapy using microcurrents that are delivered via two electrodes worn on the earlobes. Active CES devices will be pre-programmed by the manufacturer to deliver a bipolar, asymmetric rectangular waveform at a current of 100 µa, a level that is generally undetectable by the wearer of the device. At these settings, the manufacturer recommends a treatment duration of 60 minutes. Participants will not be able to alter the settings in any way.
Study NCT02419014 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Device
Description: The inactive (sham) devices look identical to the active device but are inactivated by the manufacturer so as not to deliver any electrical current.
Study NCT03201770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyronaridine artesunate
Description: Antimalarial treatment
Study NCT03156842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan/Amlodipine, Rosuvastatin
Description: A fixed dose combination tablet of Fimasartan and Amlodipine and Rosuvastatin will be administrated once daily on treatment period.
Study NCT03156842 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan/Amlodipine
Description: A fixed dose combination tablet of Fimasartan and Amlodipine will be administrated once daily on treatment period.
Study NCT03156842 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan, Rosuvastatin
Description: Fimasartan and Rosuvastatin will be administrated once daily on treatment period.
Study NCT02590575 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Extracorporeal CO2 removal with the Prismalung(R) gas exchanger on the Prismaflex(R) renal replacement platform
Description: 1. With ongoing continuous hemofiltration and mechanical ventilation additional membrane gas exchange device (Prismalung®) in the renal replacement circulation; measurements of the effects on PaCO2 under varying blood and sweep gas flows~2. Afterwards, reduction of the tidal volume (VT) / plateau pressure until reaching the initial PaCO2value
Study NCT00737347 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle modification
Description: lifestyle intervention includes meal planning, food preparation, food label reading, dining out, and physical activity counseling
Study NCT00990392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polysporin Triple Therapy ointment
Description: Polysporin Triple Therapy ointment applied to the insertion point at the time of CVC placement and twice within the first week.
Study NCT00990392 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Petroleum Jelly
Description: Petroleum jelly applied to the insertion point at the time of CVC placement and twice within the first week.
Study NCT04737798 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oil pulling with coconut oil
Description: using oil pulling therapy with coconut oil
Study NCT04737798 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: oil pulling with sesame oil
Description: using oil pulling therapy with sesame oil
Study NCT03403296 — intervention group
Intervention type: GENETIC
Intervention: nProfiler I Stomach Cancer Assay Kit
Description: qPCR by nProfiler I Stomach Cancer Assay Kit
Study NCT00276991 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Kallunk oxide (Immunotherapy) 
Description: The study was assigned only one Arm >450 cu/mm\^3 of baseline CD + T cells. HIV type-1 subjects were received one drug, a daily regimen of Kallunk oxide(Immunotherapy) + Long Pepper, that is a combination of a traditional alternative medicine(Complementary and Alternative Medicine CAM) as Kallunk oxide and appropriate drug carrier antidote. The drug assigns to 0.100 mg and 0.200 mg Kallunk oxide molecules with 199.900 mg, and 499.800 mg Antidote( This antidote was used as a carrier of Kallunk oxide molecules), respectively, for children and adults. Dosage: 200 mg for children and 500 mg for adults. This powder form sample size product was administered once daily dose on 5 days treatment. The Botanical name of the antidote is Piper Longum.
Study NCT03743324 — intervention group
Intervention type: PROCEDURE
Intervention: Immediate Breast reconstruction
Description: Immediate Autologous/prosthetic-based breast reconstruction is performed after mastectomy on the breast that is diagnosed with breast cancer
Study NCT03743324 — intervention group
Intervention type: PROCEDURE
Intervention: Delayed Breast Reconstruction
Description: Delayed Autologous/prosthetic-based breast reconstruction is performed after mastectomy on the breast that is diagnosed with breast cancer
Study NCT03743324 — intervention group
Intervention type: RADIATION
Intervention: Radiation
Description: Radiation is performed to the surgical site and complies with the ASCO guidelines on post-mastectomy radiotherapy
Study NCT01576445 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mid-vastus approach
Description: Mid-vastus approach to avoid patellar eversion and to minimise the muscle split.
Study NCT01576445 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: medial parapatellar approach
Description: medial parapatellar approach
Study NCT01927549 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate multivessel PCI
Study NCT01927549 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Culprit Lesion only PCI
Study NCT03826628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rapamycin
Description: Apply to the affected area once a day, approximately half an hour before retiring for bed in the evening, for 26 weeks
Study NCT03826628 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Apply to the affected area once a day, approximately half an hour before retiring for bed in the evening, for 26 weeks
Study NCT00750139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAFT-500
Description: topical cream 1 application every day up to 4 weeks weeks
Study NCT00750139 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 2-weeks
Description: placebo cream 1 application every day for up to 4 weeks
Study NCT00750139 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naftin 1%
Description: topical allylamine cream applied once a day for up to 4 weeks
Study NCT00750139 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 4-weeks
Description: topical placebo cream applied once a day for up to 4 weeks
Study NCT03093649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: adverse events using patient-reported outcomes version of common terminology criteria for adverse events (PRO-CTCAE) questionaire
Description: The intervention was administrated through APP
Study NCT03093649 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: do not report adverse events through patient-reported outcomes version of common terminology criteria for adverse events (PRO-CTCAE) questionaire
Description: patients receive normal care and visit
Study NCT01865201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edaravone
Description: Be used at a dose of 30mg, intravenously, twice per day, for 14 days.
Study NCT01865201 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Common fundamental management
Description: common fundamental management, which was as follows: ①Methylprednisolone, administered by intravenous infusion at a 500mg daily for 3 consecutive days and then gradually tailed off in 30 days with administration of oral prednisolone. ②Dehydration drugs.
Study NCT02659917 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: -Glass ionomer cement-
Description: Atraumatic Restorative Treatment
Study NCT02836158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-IDARAM plus intrathecal chemotherapy
Description: R-IDARAM comprised of rituximab 375 mg/m2 (day 1), idarubicin 10 mg/m2(day 2); dexamethasone 100 mg/m2 (12 h.infusion in day 2, 3 and 4); cytarabine 1 g/m2 (1 h. infusion in day 2); methotrexate 1.5 g/m2 (6 h. infusion in day 4 with folinic acid rescue). Intrathecal Immunochemotherapy comprised of rituximab 20mg, MTX 15mg, dexamethasone 5mg and Ara-c 50mg once a week.
Study NCT01896635 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FMT infusions
Description: Active FMT derived from healthy anonymous pre-screened donors
Study NCT01896635 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo infusion
Description: Placebo infusion not containing any donor microbial material
Study NCT03432884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-3111
Description: Subjects will receive BGB-3111
Study NCT03432884 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive Placebo
Study NCT02068781 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low-sodium diet
Description: 50 mmol NaCl per 24h
Study NCT02068781 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High-sodium diet
Description: 250 mmol NaCl per 24h
Study NCT03432884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive Placebo
Study NCT03432884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Subjects will receive Moxifloxicin
Study NCT01101360 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Matrix RF
Description: Section of port wine stain to be treated 5 times every 5 weeks (+/- 1 week)
Study NCT01101360 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Matrix RF followed by Pulse Dye Laser
Description: Section of port wine stain to be treated 5 times every 5 weeks (+/- 1 week)